Biohaven Ltd
BHVNHealthcare|Biotechnology|USA
$15.55
-1.24 (-7.39%)
Tangible Book
$0.73
Clinical Trials (42)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06976268 A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | Parkinson Disease | P2P3 | Recruiting | 550 | RCT, Double-blind | BHV-8000 10mg, BHV-8000 20 mg, Placebo |
| NCT07661056 Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease | Graves Disease | P3 | Recruiting | 300 | RCT, Double-blind | BHV-1300, Placebo |
| NCT06132893 A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Focal Epilepsy | P2P3 | Recruiting | 390 | RCT, Double-blind | BHV-7000, BHV-7000, Placebo, BHV-7000, Placebo |
| NCT06309966 Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Focal Epilepsy | P2P3 | Active | 390 | RCT, Double-blind | BHV-7000, BHV-7000, Placebo |
| NCT03701399 Troriluzole in Adult Participants With Spinocerebellar Ataxia | Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1 | P3 | Active | 299 | RCT, Double-blind | troriluzole, Placebo |
| NCT05337553 A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy | Spinal Muscular Atrophy, Neuromuscular Diseases | P3 | Active | 269 | RCT, Double-blind | taldefgrobep alfa, Placebo, taldefgrobep alfa |
| NCT03970447 A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Glioblastoma | P2P3 | Recruiting | 2,250 | RCT, Open-label | Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine |
| NCT07281495 Taldefgrobep Alfa in Adults With Overweight and Obesity | Obesity, Overweight | P2 | Active | 150 | RCT, Double-blind | Taldefgrobep Alfa, Placebo, Taldefgrobep Alfa, Placebo |
| NCT06384807 A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Solid Tumor | P1P2 | Recruiting | 500 | Open-label | BHV-1510, Cemiplimab, BHV-1510, BHV-1510, Cemiplimab |
| NCT06874335 A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | Solid Tumor | P1 | Recruiting | 140 | Open-label | BHV-1530, Cemiplimab |
| NCT06980649 Study of BHV-1300 in Graves' Disease | Graves Disease | P1 | Recruiting | 15 | Open-label | BHV-1300 |
| NCT07054684 Study of BHV-1400 in IgA Nephropathy | IgA Nephropathy | P1 | Recruiting | 20 | Open-label | BHV-1400 |
| NCT07125261 BHV-7000 Responsive Neurostimulation System (RNS) Study | Epilepsy, Seizures | P1 | Active | 5 | Open-label | BHV-700 |
| NCT06419322 Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA). | Spinal Muscular Atrophy | N/A | Active | 14 | Open-label | — |
| NCT06529146 Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control | Spinocerebellar Ataxias | Active | 909 | — | BHV-4157 | |
| NCT06552260 A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma | Glioblastoma, Recurrent Glioblastoma | Early P1 | Recruiting | 27 | RCT, Open-label | Troriluzole |
| NCT07642050 A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy | IgA Nephropathy | P3 | Not Yet Recruiting | 420 | RCT, Double-blind | BHV-1400, Placebo |
| NCT06425159 A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures | Generalized Epilepsy | P2P3 | Terminated | 27 | RCT, Double-blind | BHV-7000, Placebo |
| NCT06419582 BHV-7000 Acute Treatment of Bipolar Mania | Bipolar Disorder | P2P3 | Completed | 274 | RCT, Double-blind | BHV-7000, Placebo |
| NCT03829241 Randomized Trial of Adult Participants With Generalized Anxiety Disorder | Generalized Anxiety Disorder | P3 | Completed | 881 | RCT, Double-blind | Troriluzole, Placebo |
| NCT03299166 Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder | Obsessive-Compulsive Disorder | P2P3 | Completed | 426 | RCT, Double-blind | Troriluzole, Placebo |
| NCT04436510 HEALEY ALS Platform Trial - Regimen B Verdiperstat | Amyotrophic Lateral Sclerosis | P2P3 | Completed | 167 | RCT, Double-blind | Matching Placebo, Verdiperstat |
| NCT03952806 Study of BHV-3241 in Participants With Multiple System Atrophy | Multiple System Atrophy | P3 | Completed | 421 | RCT, Double-blind | Verdiperstat, Placebo |
| NCT04693351 A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder | Obsessive-Compulsive Disorder | P3 | Completed | 589 | RCT, Double-blind | Troriluzole, Placebo |
| NCT03017508 Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder | Social Anxiety Disorder, Performance Anxiety | P2P3 | Completed | 22 | RCT, Double-blind | BHV-0223, Placebo |
| NCT02960893 Trial in Adult Participants With Spinocerebellar Ataxia (SCA) | Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1 | P2P3 | Completed | 141 | RCT, Double-blind | Troriluzole, Placebo, Troriluzole |
| NCT04708834 Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder | Obsessive Compulsive Disorder | P3 | Terminated | 772 | Open-label | Troriluzole (BHV-4157) |
| NCT04641143 Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder | Obsessive-Compulsive Disorder | P3 | Completed | 456 | RCT, Double-blind | Troriluzole, Placebo |
| NCT06443463 Long-term Safety and Tolerability of BHV-7000 | Focal Epilepsy | P2 | By Invite | 660 | Open-label | BHV-7000, BHV-7000 |
| NCT06423781 Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) | Major Depressive Disorder | P2 | Completed | 233 | Open-label | BHV-7000 |
| NCT06423794 BHV-7000 Open-Label Extension Bipolar Mania Study | Bipolar Disorder | P2 | Terminated | 94 | Open-label | BHV-7000 |
| NCT06603623 Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine | Migraine | P2 | Completed | 647 | RCT, Double-blind | BHV-2100, BHV-2100, Placebo |
| NCT06419608 Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression | Major Depressive Disorder | P2 | Completed | 336 | RCT, Double-blind | BHV-7000, Placebo |
| NCT04899921 Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | Melanoma, Metastatic Melanoma | P2 | Terminated | 1 | RCT, Double-blind | Ipilimumab, Nivolumab, Troriluzole, Placebo |
| NCT03605667 Study of BHV-4157 in Alzheimer's Disease | Alzheimer Disease | P2 | Completed | 350 | RCT, Double-blind | troriluzole, Placebo oral capsule |
| NCT07262268 A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia | Familial Erythromelalgia | P1 | By Invite | 5 | RCT, Double-blind | BHV-7000, Placebo |
| NCT04634435 Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients | Multiple Myeloma | P1 | Completed | 7 | Open-label | — |
| NCT03520517 Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS | Amyotrophic Lateral Sclerosis, ALS | P1 | Completed | 22 | Open-label | BHV-0223 |
| NCT03537807 Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis, ALS | NO_LONGER_AVAILABLE | — | — | Riluzole | |
| NCT04616456 Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients | Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant | Early P1 | Completed | 19 | Open-label | [F-18]PBR06, Verdiperstat |
| NCT06034886 Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA) | SCA, Spinocerebellar Ataxias | AVAILABLE | — | — | Troriluzole | |
| NCT05086094 Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA) | Multiple System Atrophy (MSA) | NO_LONGER_AVAILABLE | — | — | BHV3241, verdiperstat |